ORCID as entered in ROS
![orcid_icon](/themes/resgate8/images/icons/ORCIDiD_icon24x24.png)
Select Publications
2021, 'The effects of dipeptidyl peptidase-4 inhibitors on kidney outcomes', Diabetes, Obesity and Metabolism, 23, pp. 763 - 773, http://dx.doi.org/10.1111/dom.14281
,2021, 'The International Society of Nephrology Advancing Clinical Trials (ISN-ACT) Network: current activities and future goals', Kidney International, 99, pp. 551 - 554, http://dx.doi.org/10.1016/j.kint.2020.10.048
,2021, 'An exploration of the heterogeneity in effects of SGLT2 inhibition on cardiovascular and all-cause mortality in the EMPA-REG OUTCOME, CANVAS Program, DECLARE-TIMI 58, and CREDENCE trials', International Journal of Cardiology, 324, pp. 165 - 172, http://dx.doi.org/10.1016/j.ijcard.2020.09.050
,2021, 'Comparison of Circulating Biomarkers in Predicting Diabetic Kidney Disease Progression With Autoantibodies to Erythropoietin Receptor', Kidney International Reports, 6, pp. 284 - 295, http://dx.doi.org/10.1016/j.ekir.2020.10.039
,2021, 'Inter-individual variability in atrasentan exposure partly explains variability in kidney protection and fluid retention responses: A post hoc analysis of the SONAR trial', Diabetes, Obesity and Metabolism, 23, pp. 561 - 568, http://dx.doi.org/10.1111/dom.14252
,2021, 'Sodium-glucose co-transporter-2 inhibitors with and without metformin: A meta-analysis of cardiovascular, kidney and mortality outcomes', Diabetes, Obesity and Metabolism, 23, pp. 382 - 390, http://dx.doi.org/10.1111/dom.14226
,2021, 'Choice of endpoint in kidney outcome trials: Considerations from the EMPA-REG OUTCOMEVR trial', Nephrology Dialysis Transplantation, 35, pp. 2103 - 2111, http://dx.doi.org/10.1093/NDT/GFZ179
,2021, 'Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes: The CARMELINA randomized controlled trial', Clinical Kidney Journal, 14, pp. 226 - 236, http://dx.doi.org/10.1093/ckj/sfaa225
,2021, 'Forever starts now: Effects of glucose-lowering therapies on acute kidney injury', Clinical Journal of the American Society of Nephrology, 16, pp. 6 - 8, http://dx.doi.org/10.2215/CJN.18141120
,2021, 'Kidney, cardiovascular, and safety outcomes of canagliflozin according to baseline albuminuria a credence secondary analysis', Clinical Journal of the American Society of Nephrology, 16, pp. 384 - 395, http://dx.doi.org/10.2215/CJN.15260920
,2021, 'Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program', American Journal of Kidney Diseases, 77, pp. 23 - 34.e1, http://dx.doi.org/10.1053/j.ajkd.2020.06.018
,2021, 'Sodium-glucose co-transporter-2 inhibition and ocular outcomes in patients with type 2 diabetes: A systematic review and meta-analysis', Diabetes, Obesity and Metabolism, 23, pp. 252 - 257, http://dx.doi.org/10.1111/dom.14197
,2021, 'Sodium-glucose cotransporter 2 inhibition: Which patient with chronic kidney disease should be treated in the future?', Nephrology Dialysis Transplantation, 35, pp. I48 - I55, http://dx.doi.org/10.1093/NDT/GFZ252
,2021, 'ASCEND Program: Efficacy and Safety from ASCEND-D and -ND and Overall MACE Finding', Journal of the American Society of Nephrology, 32, pp. B2 - B3, http://dx.doi.org/10.1681/asn.20213210s1b2c
,2021, 'Circulating Metabolites to Predict Renal Outcomes in CANVAS Type 2 Diabetes Mellitus Population', Journal of the American Society of Nephrology, 32, pp. 47 - 47, http://dx.doi.org/10.1681/asn.20213210s147a
,2021, 'Corrigendum', ESC Heart Failure, 8, pp. 3447 - 3447, http://dx.doi.org/10.1002/ehf2.13408
,2021, 'Effects of Canagliflozin (CANA) on Kidney Outcomes: Pooled Analyses from the CANVAS Program and CREDENCE', Journal of the American Society of Nephrology, 32, pp. 263 - 264, http://dx.doi.org/10.1681/asn.20213210s1263b
,2021, 'IL-6 Inhibitor Ziltivekimab Increases Serum Hemoglobin and Iron Biomarkers in Patients with CKD Stage 3-5: A RESCUE Trial Analysis', Journal of the American Society of Nephrology, 32, pp. 190 - 190, http://dx.doi.org/10.1681/asn.20213210s1190c
,2021, 'The Effect of Atrasentan on Kidney and Heart Failure Outcomes by Baseline Albuminuria and Kidney Function: A Post Hoc Analysis of the SONAR Trial', Journal of the American Society of Nephrology, 32, pp. 728 - 728, http://dx.doi.org/10.1681/asn.20213210s1728b
,2020, 'Effects of canagliflozin in patients with baseline eGFR <30 ml/min per 1.73 m2: Subgroup analysis of the randomized CREDENCE trial', Clinical Journal of the American Society of Nephrology, 15, pp. 1705 - 1714, http://dx.doi.org/10.2215/CJN.10140620
,2020, 'Higher-dose sitagliptin and the risk of congestive heart failure in older adults with CKD', Clinical Journal of the American Society of Nephrology, 15, pp. 1728 - 1739, http://dx.doi.org/10.2215/CJN.08310520
,2020, 'Early change in albuminuria with canagliflozin predicts kidney and cardiovascular outcomes: A post hoc analysis from the Credence trial', Journal of the American Society of Nephrology, 31, pp. 2925 - 2936, http://dx.doi.org/10.1681/ASN.2020050723
,2020, 'A randomized trial on the effect of phosphate reduction on vascular end points in CKD (improve-CKD)', Journal of the American Society of Nephrology, 31, pp. 2653 - 2666, http://dx.doi.org/10.1681/ASN.2020040411
,2020, 'Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial', The Lancet Diabetes and Endocrinology, 8, pp. 903 - 914, http://dx.doi.org/10.1016/s2213-8587(20)30300-4
,2020, 'Effects of canagliflozin on initiation of insulin and other antihyperglycaemic agents in the CANVAS Program', Diabetes, Obesity and Metabolism, 22, pp. 2199 - 2203, http://dx.doi.org/10.1111/dom.14143
,2020, 'Response to: Loutradis et al. Longer Dialysis Sessions Improve Cardiac Systolic Function by Reducing Myocardial Stunning', Journal of Cardiac Failure, 26, pp. 1028 - 1029, http://dx.doi.org/10.1016/j.cardfail.2020.09.001
,2020, 'The effects of combination canagliflozin and glucagon-like peptide-1 receptor agonist therapy on intermediate markers of cardiovascular risk in the CANVAS program', International Journal of Cardiology, 318, pp. 126 - 129, http://dx.doi.org/10.1016/j.ijcard.2020.06.011
,2020, 'Different eGFR decline thresholds and renal effects of canagliflozin: Data from the CANVAS program', Journal of the American Society of Nephrology, 31, pp. 2446 - 2456, http://dx.doi.org/10.1681/ASN.2019121312
,2020, 'Empagliflozin and cardiovascular and kidney outcomes across KDIGO risk categories: Post hoc analysis of a randomized, double-blind, placebo-controlled, multinational trial', Clinical Journal of the American Society of Nephrology, 15, pp. 1433 - 1444, http://dx.doi.org/10.2215/CJN.14901219
,2020, 'International consensus definitions of clinical trial outcomes for kidney failure: 2020', Kidney International, 98, pp. 849 - 859, http://dx.doi.org/10.1016/j.kint.2020.07.013
,2020, 'No evidence of a legacy effect on survival following randomization to extended hours dialysis in the ACTIVE Dialysis trial', Nephrology, 25, pp. 792 - 800, http://dx.doi.org/10.1111/nep.13737
,2020, 'The impact of the COVID-19 pandemic on medical education', Medical Journal of Australia, 213, pp. 334 - 334.e1, http://dx.doi.org/10.5694/mja2.50762
,2020, 'Haemodialysis duration, frequency and intensity for end-stage kidney disease', Cochrane Database of Systematic Reviews, 2020, http://dx.doi.org/10.1002/14651858.CD010064.pub2
,2020, 'Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes', Kidney International, 98, pp. 769 - 777, http://dx.doi.org/10.1016/j.kint.2020.04.051
,2020, 'Comparative efficacy and safety of bp-lowering pharmacotherapy in patients undergoing maintenance dialysis: A network meta-analysis of randomized, controlled trials', Clinical Journal of the American Society of Nephrology, 15, pp. 1129 - 1138, http://dx.doi.org/10.2215/CJN.12201019
,2020, 'Effects of linagliptin on cardiovascular and kidney outcomes in people with normal and reduced kidney function: Secondary analysis of the carmelina randomized trial', Diabetes Care, 43, pp. 1803 - 1812, http://dx.doi.org/10.2337/dc20-0279
,2020, 'Effects of allopurinol on the progression of chronic kidney disease', New England Journal of Medicine, 382, pp. 2504 - 2513, http://dx.doi.org/10.1056/NEJMoa1915833
,2020, '27-OR: Effect of Canagliflozin on Total Hospitalization for Heart Failure Events in Patients with Type 2 Diabetes and Chronic Kidney Disease', Diabetes, 69, http://dx.doi.org/10.2337/db20-27-or
,2020, 'MO051EFFECTS OF SEMAGLUTIDE ON CHRONIC KIDNEY DISEASE OUTCOMES: A POST HOC POOLED ANALYSIS FROM THE SUSTAIN 6 AND PIONEER 6 TRIALS', Nephrology Dialysis Transplantation, 35, http://dx.doi.org/10.1093/ndt/gfaa140.mo051
,2020, 'P1013CANAGLIFLOZIN AND RISK OF GENITAL INFECTIONS AND URINARY TRACT INFECTIONS IN PEOPLE WITH DIABETES MELLITUS AND KIDNEY DISEASE- A POST-HOC ANALYSIS OF THE CREDENCE TRIAL', Nephrology Dialysis Transplantation, 35, pp. gfaa142.p1013, http://dx.doi.org/10.1093/ndt/gfaa142.p1013
,2020, 'P1019CANAGLIFLOZIN AND RISK OF SKIN AND SOFT TISSUE INFECTIONS IN PEOPLE WITH DIABETES MELLITUS AND KIDNEY DISEASE - A POST-HOC ANALYSIS OF THE CREDENCE TRIAL', Nephrology Dialysis Transplantation, 35, http://dx.doi.org/10.1093/ndt/gfaa142.p1019
,2020, 'P1028EFFECTS OF CANAGLIFLOZIN ON MAJOR ADVERSE CARDIOVASCULAR OUTCOMES IN PATIENTS WITH DIFFERENT BASELINE LEVELS OF TYPE 2 DIABETES MELLITUS DISEASE SEVERITY: RESULTS FROM THE CANVAS PROGRAM', Nephrology Dialysis Transplantation, 35, pp. gfaa142.p1028, http://dx.doi.org/10.1093/ndt/gfaa142.p1028
,2020, 'Predictors of Change in Left-Ventricular Structure and Function in a Trial of Extended Hours Hemodialysis', Journal of Cardiac Failure, 26, pp. 482 - 491, http://dx.doi.org/10.1016/j.cardfail.2020.03.010
,2020, 'TO002REDUCTION IN THE RATE OF EGFR DECLINE WITH SEMAGLUTIDE VS PLACEBO: A POST HOC POOLED ANALYSIS OF SUSTAIN 6 AND PIONEER 6', Nephrology Dialysis Transplantation, 35, http://dx.doi.org/10.1093/ndt/gfaa141.to002
,2020, 'The effect of canagliflozin on amputation risk in the CANVAS program and the CREDENCE trial.', Diabetes Obes Metab, 22, pp. 1753 - 1766, http://dx.doi.org/10.1111/dom.14091
,2020, 'The impact of COVID-19 pandemic on medical education', Medical Journal of Australia, 213, pp. 188 - 188.e1, http://dx.doi.org/10.5694/mja2.50705
,2020, 'Renal, cardiovascular, and safety outcomes of canagliflozin by baseline kidney function: A secondary analysis of the CREDENCE randomized trial', Journal of the American Society of Nephrology, 31, pp. 1128 - 1139, http://dx.doi.org/10.1681/ASN.2019111168
,2020, 'Clinical outcomes with canagliflozin according to baseline body mass index: results from post hoc analyses of the CANVAS Program', Diabetes, Obesity and Metabolism, 22, pp. 530 - 539, http://dx.doi.org/10.1111/dom.13920
,2020, 'Linagliptin and cardiorenal outcomes in Asians with type 2 diabetes mellitus and established cardiovascular and/or kidney disease: subgroup analysis of the randomized CARMELINA® trial', Diabetology International, 11, pp. 129 - 141, http://dx.doi.org/10.1007/s13340-019-00412-x
,2020, 'Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c <7%: Results From the CREDENCE Trial', Circulation, 141, pp. 407 - 410, http://dx.doi.org/10.1161/CIRCULATIONAHA.119.044359
,